---

Clinical Report: Fibrosis of the Liver in Metabolic Dysfunction-Related Steatotic Liver Disease

Overview

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease globally, significantly linked to cardiometabolic comorbidities. The detection of hepatic fibrosis is crucial as it predicts liver-related events and mortality.

Background

MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), affects over 30% of the adult population worldwide. It is associated with increased risks of cardiovascular diseases and liver-related complications, particularly in patients with advanced fibrosis.

Data Highlights

Recent studies indicate that the prevalence of MASLD is rising, with estimates suggesting that it affects approximately 25% of adults in the United States. Additionally, the progression of fibrosis occurs in 20% to 30% of patients with MASLD, and the risk of developing cirrhosis is significantly higher in those with metabolic syndrome. Furthermore, the economic burden of MASLD-related complications is substantial, with healthcare costs projected to exceed $100 billion annually in the U.S. alone.

Key Findings

• MASLD is the most common etiology of chronic liver disease, affecting over 30% of adults globally.

• The pooled incidence rate for all-cause mortality among individuals with MASLD is 12.6 per 1000 person-years.

• Among patients with metabolic dysfunction-associated steatohepatitis (MASH), 25%-33% will experience fibrosis progression.

• Fibrosis staging is critical for predicting liver-related events and mortality.

Clinical Implications

Healthcare professionals should prioritize the detection of hepatic fibrosis in patients with MASLD to guide treatment decisions. The integration of lifestyle modifications and emerging pharmacotherapies may improve management strategies for patients with moderate to advanced fibrosis.

Conclusion

The rising prevalence of MASLD necessitates a comprehensive approach to its management, focusing on fibrosis detection and innovative therapeutic options.

Related Resources & Content

1. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD), 2024 -- EASL CPGs on MASLD

2. Frontiers in Immunology — Targeting macrophages in liver fibrosis

3. Frontiers in Medicine — The role of mitochondrial dynamics in metabolic dysfunction–associated steatotic liver disease

4. Frontiers in Pediatrics — Gut microbiota and pediatric metabolic dysfunction–associated steatotic liver disease: clinical evidence and therapeutic implications

5. The New Gastroenterologist — Addressing NAFLD: Strategies to Alleviate the Effects of Nonalcoholic Fatty Liver Disease

6. FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’

7. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

8. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

9. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis - PubMed

10. Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE Thresholds and Diagnostic Accuracies for Detecting Hepatic Fibrosis in Patients with MASLD: A Systematic Review and Meta-Analysis - PMC

11. Drug Trials Snapshots: REZDIFFRA | FDA

12. Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease | AASLD

13. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis | New England Journal of Medicine

14. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | New England Journal of Medicine

---